Capricor Therapeutics Inc (CAPR) Dividend History

Company News

• ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

  Rosen Law Firm filed a class action lawsuit against Capricor Therapeutics for allegedly providing misleading statements about its cell therapy drug deramiocel and its Phase 2 HOPE-2 trial data, potentially causing shareholders to purchase securities at artificially inflated prices.

  GlobeNewswire Inc.
• CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

  The Schall Law Firm is investigating claims against Capricor Therapeutics, Inc. for potential violations of securities laws. The investigation focuses on whether the company issued false or misleading statements regarding its Biologics License Application for deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy.

  Benzinga
• Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

  Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.

  Zacks Investment Research
• 5 Hot Penny Stocks To Watch After Big News Today

  5 hot penny stocks to watch after big news. The post 5 Hot Penny Stocks To Watch After Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: APM CKPT IMRA MNMD